MedImmune-Genentech Battle Moves To High Court

Law360, New York (February 21, 2006, 12:00 AM EST) -- Biotechnology company MedImmune Inc. gained another chance to fight off rival Genentech Inc. this week, with the U.S. Supreme Court agreeing to hear the previously dismissed case centering on whether a company must refuse to pay royalties before challenging a patent claim.

MedImmune has long been defending patent claims against Genentech for methods MedImmune uses to make Synagis, a drug designed to prevent dangerous respiratory tract infections in infants.

In 2003, MedImmune sued Genentech in the U.S. District Court for the Central District of California, seeking...
To view the full article, register now.